ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.
Saved in:
| Title: | ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors. |
|---|---|
| Authors: | Nie, Wei1 (AUTHOR), Wang, Zhi-Jie2 (AUTHOR), Zhang, Kai3 (AUTHOR), Li, Bing4 (AUTHOR), Cai, Yi-Ran4 (AUTHOR), Wen, Feng-Cai5 (AUTHOR), Zhang, Ding5 (AUTHOR), Bai, Yue-Zong5 (AUTHOR), Zhang, Xue-Yan1 (AUTHOR), Wang, Shu-Yuan1 (AUTHOR), Cheng, Lei1 (AUTHOR), Zhong, Hua1 (AUTHOR) eddiedong8@hotmail.com, Liu, Li3 (AUTHOR) liulist2013@163.com, Wang, Jie2 (AUTHOR) zlhuxi@163.com, Han, Bao-Hui1 (AUTHOR) 18930858216@163.com |
| Source: | BMC Medicine. 5/5/2022, Vol. 20 Issue 1, p1-12. 12p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
